Targeted therapy in locally and metastatic recurrent cervical cancers

Romain Geiss; Thibault De La Motte Rouge; Coraline Dubot; Alexandra Leary; Catherine Lhommé; Patricia Pautier; Suzy Scholl; Manuel Jorge Rodrigues

Targeted therapy in locally and metastatic recurrent cervical cancers

Romain Geiss, Thibault De La Motte Rouge, Coraline Dubot, Alexandra Leary, Catherine Lhommé, Patricia Pautier, Suzy Scholl, Manuel Jorge Rodrigues

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Doublet chemotherapy with cisplatin is the reference for the treatment of recurrent cervical cancer. However, those tumors are little chemo-sensitive and overall survival remains poor. Moreover, because of pelvic irradiation, toxicities, especially hematologic toxicities, are increased and require a drug dose reduction. Finally, these treatments are rarely effective in radiation areas. Given all these elements, the development of new therapies is a prominent issue. This article reviews the results of the major targeted therapies in cervical cancer. Anti-EGFRs are disappointing despite of a strong biological rational. On the other hand, bevacizumab is the first targeted therapy to show a significant increase of overall survival. A major effort must be made in translational research for a better understanding of tumor biology of these tumors.

Translated title of the contribution	Thérapies ciblées dans les cancers du col de l'utérus en évolution locale ou métastatique
Original language	English
Pages (from-to)	479-498
Number of pages	20
Journal	Bulletin du Cancer
Volume	101
Issue number	7-8
Publication status	Published - 1 Jul 2014

Keywords

Bevacizumab
Cervical cancer
EGFR
Targeted therapy

Cite this

@article{ecdcdf1ddab549608ebdc2f62874b873,

title = "Targeted therapy in locally and metastatic recurrent cervical cancers",

abstract = "Doublet chemotherapy with cisplatin is the reference for the treatment of recurrent cervical cancer. However, those tumors are little chemo-sensitive and overall survival remains poor. Moreover, because of pelvic irradiation, toxicities, especially hematologic toxicities, are increased and require a drug dose reduction. Finally, these treatments are rarely effective in radiation areas. Given all these elements, the development of new therapies is a prominent issue. This article reviews the results of the major targeted therapies in cervical cancer. Anti-EGFRs are disappointing despite of a strong biological rational. On the other hand, bevacizumab is the first targeted therapy to show a significant increase of overall survival. A major effort must be made in translational research for a better understanding of tumor biology of these tumors.",

keywords = "Bevacizumab, Cervical cancer, EGFR, Targeted therapy",

author = "Romain Geiss and {De La Motte Rouge}, Thibault and Coraline Dubot and Alexandra Leary and Catherine Lhomm{\'e} and Patricia Pautier and Suzy Scholl and Rodrigues, {Manuel Jorge}",

note = "Publisher Copyright: {\textcopyright} 2014 John Libbey Eurotext.",

year = "2014",

month = jul,

day = "1",

language = "English",

volume = "101",

pages = "479--498",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "7-8",

}

TY - JOUR

T1 - Targeted therapy in locally and metastatic recurrent cervical cancers

AU - Geiss, Romain

AU - De La Motte Rouge, Thibault

AU - Dubot, Coraline

AU - Leary, Alexandra

AU - Lhommé, Catherine

AU - Pautier, Patricia

AU - Scholl, Suzy

AU - Rodrigues, Manuel Jorge

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Doublet chemotherapy with cisplatin is the reference for the treatment of recurrent cervical cancer. However, those tumors are little chemo-sensitive and overall survival remains poor. Moreover, because of pelvic irradiation, toxicities, especially hematologic toxicities, are increased and require a drug dose reduction. Finally, these treatments are rarely effective in radiation areas. Given all these elements, the development of new therapies is a prominent issue. This article reviews the results of the major targeted therapies in cervical cancer. Anti-EGFRs are disappointing despite of a strong biological rational. On the other hand, bevacizumab is the first targeted therapy to show a significant increase of overall survival. A major effort must be made in translational research for a better understanding of tumor biology of these tumors.

AB - Doublet chemotherapy with cisplatin is the reference for the treatment of recurrent cervical cancer. However, those tumors are little chemo-sensitive and overall survival remains poor. Moreover, because of pelvic irradiation, toxicities, especially hematologic toxicities, are increased and require a drug dose reduction. Finally, these treatments are rarely effective in radiation areas. Given all these elements, the development of new therapies is a prominent issue. This article reviews the results of the major targeted therapies in cervical cancer. Anti-EGFRs are disappointing despite of a strong biological rational. On the other hand, bevacizumab is the first targeted therapy to show a significant increase of overall survival. A major effort must be made in translational research for a better understanding of tumor biology of these tumors.

KW - Bevacizumab

KW - Cervical cancer

KW - EGFR

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84907099578&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84907099578

SN - 0007-4551

VL - 101

SP - 479

EP - 498

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 7-8

ER -

Targeted therapy in locally and metastatic recurrent cervical cancers

Abstract

Keywords

Other files and links

Cite this